Videos

Where a patient lives may affect what kind of treatment they are offered for their CLL or SLL. However, second opinions and learning about one’s cancer diagnosis can help.

An artificial intelligence platform was able to tell the difference between patients with prefibrotic primary myelofibrosis and essential thrombocythemia. However, an expert says that there are considerations that patients must remember when it comes to the use of such programs.

A triple-negative breast cancer survivor discussed disparities she faced when undergoing cancer care.

The panel concludes their discussion with a conversation about the myths surrounding the treatment of cervical cancer.

Experts on cervical cancer offer provide comprehensive insights on the challenges patients experience and discuss ways to improve care.

Cervical cancer survival and Cervivor ambassador Kate Weissman provides advice on conversations patients with cervical cancer should be having with their care teams.

Patients with metastatic breast cancer receiving HER2-targeted therapies should promptly report any respiratory symptoms or signs of lung and heart disease to their oncology care team to facilitate early intervention and management of side effects.

Patients on HER2-targeted therapies for HER2-positive metastatic breast cancer should be vigilant about potential side effects like heart toxicities and interstitial lung disease and should undergo regular heart function monitoring and lung scans to catch these side effects early.

Imaging scans provide an invaluable method of monitoring response to HER2-positive breast cancer treatment; frequency of imaging scans depends on individual patient response, symptoms, and the need to monitor for side effects such as interstitial lung disease.

HER2-targeted therapies improve outcomes by shutting down growth signaling to cancer cells, targeted delivery of chemotherapy, or blocking intracellular signaling - all leveraging the HER2 receptor to better control metastatic breast cancer.

Treatment for HER2 low metastatic breast cancer may utilize HER2-targeted antibody-drug conjugates like T-DM1 and sacituzumab govitecan after initial therapy; knowing HER2 status, even low expression, is critical to guide use of these HER2-directed ADCs after chemotherapy.

Treatment for HER2-negative metastatic breast cancer depends on factors like hormone receptor status, with chemo/immunotherapy for PD-L1-positive triple negative disease, PARP inhibitors for BRCA mutations, and antibody-drug conjugates as options after first line therapy.

Dr Sara M. Tolaney reviews the currently available treatment options for HER2-positive metastatic breast cancer and notes that many new HER2-targeting antibody-drug conjugates and bispecific antibodies are in development.

Linda Ryan, a recurrent cervical cancer survivor and patient advocate, offers advice for patients undergoing cervical cancer treatment on advocating for yourself and communicating with family.

A gynecologic medical oncologist, a registered nurse, and a patient advocate have a conversation about shared decision-making for patients with cervical cancer.

As part of its Speaking Out® video series, CURE® spoke Dr. Gene G. Finley of Drexel University of College of Medicine and AHN Cancer Institute, Allegheny Clinic Medical Oncology, about education disparities among patients with lung cancer.

As part of its Speaking Out® video series, CURE® spoke Dr. Gene G. Finley of Drexel University of College of Medicine and AHN Cancer Institute, Allegheny Clinic Medical Oncology, about advancements in treating non-small cell lung cancer and the unmet needs that persist for patients.

As part of its Speaking Out® video series, CURE® spoke with Dusty Joy Donaldson of LiveLung/The Dusty Joy Foundation and Lung Cancer Action Network about her lung cancer journey and the importance of scans.

As part of its Speaking Out® video series, CURE® spoke with Kimberly Buchmeier, a lung cancer survivor and board member of LiveLung.

Clinical trials should be considered at any point in a patient's journey with HER2-positive metastatic breast cancer, not just when standard options are exhausted, as they provide early access to promising therapies, novel combinations, and cutting-edge care.

Sara M. Tolaney, MD, MPH explains that treatment decisions for metastatic breast cancer are based on the current biopsy showing receptor status, but prior biopsies over the full course of disease are considered as well, particularly for HER2 targeted therapies which may work even if HER2 low expression occurred years earlier.

The panel discusses unmet needs in the treatment landscape for patients with cervical cancer and the importance of clinical trials.

Comprehensive insights on the journey of a patient with cervical cancer and treatment options upon progression, with a focus on tisotumab vedotin.

In conjunction with ZERO — The End of Prostate Cancer, CURE® recently hosted the “Educated Patient® Webinar: Advancing Equity in Prostate Cancer Care.”

Sara M. Tolaney, MD, MPH, states that all breast cancers should be tested for estrogen, progesterone, and HER2 receptors; HER2 testing involves an immunohistochemistry stain to quantify protein levels, with 3+ indicating HER2+ disease, 0 indicating HER2- disease, and 1-2+ levels needing additional FISH testing to clarify HER2 status.

Sara M. Tolaney, MD, MPH, introduces the role of HER2 as a breast cancer cell growth receptor and explains HER2-positive versus HER2-negative.

Stereotactic radiation is promising in treating patients with metastatic kidney cancer and may delay the time until patients need further treatment, an expert said.

Expert perspectives on how to best match the right treatment with the right patient with cervical cancer.

Clinical insights on treatment options for patients with newly diagnosed metastatic cervical cancer, with a focus on immunotherapy and the KEYNOTE-826 trial.